WCLC 2025 - Posters & ePosters-P3.12.24 Real-World Treatment of Osimertinib Monotherapy Versus Combination Therapy in Stage IV Non-Small Cell Lung Cancer Patients

P3.12.24 Real-World Treatment of Osimertinib Monotherapy Versus Combination Therapy in Stage IV Non-Small Cell Lung Cancer Patients

Back to course

Pdf Summary

This study evaluates real-world treatment patterns for patients with stage IV non-small cell lung cancer (NSCLC) receiving osimertinib either as monotherapy (osi-mono) or in combination with chemotherapy (osichemo) following FDA approval in February 2024 based on the FLAURA-2 trial, which showed progression-free survival benefits for combination therapy.<br /><br />Using the Integra Connect PrecisionQ database, 235 patients aged 18 or older diagnosed with stage IV NSCLC who initiated frontline treatment between February and December 2024 were analyzed. The study assessed the influence of clinical and demographic variables—age, sex, race, ECOG performance status, provider patient volume, disease stage, radiation therapy, and brain/CNS metastases—on the choice between osi-mono and osichemo.<br /><br />Results revealed that younger patients and those with more advanced disease stages were more likely to receive osichemo. While sex, race, ECOG status, and provider volume did not reach statistical significance, trends indicated higher osichemo use among patients with better ECOG scores and those treated by providers with higher NSCLC patient volumes. Other factors such as presence of brain/CNS metastases and receipt of radiation therapy showed no clear association with therapy choice.<br /><br />Overall, only 29% of metastatic NSCLC patients treated with osimertinib received combination chemotherapy in the real-world setting during this period. The findings suggest clinical decisions are influenced mainly by patient age and disease stage, with some trends related to functional status and provider experience. Further analyses incorporating updated survival data from FLAURA-2 are warranted to understand how evolving evidence may impact the adoption of osimertinib combination therapy in practice.

Asset Subtitle

Edgardo S. Santos

Meta Tag

Speaker Edgardo S. Santos

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

stage IV non-small cell lung cancer

NSCLC

osimertinib monotherapy

osimertinib combination therapy

FLAURA-2 trial

progression-free survival

Integra Connect PrecisionQ database

treatment patterns

clinical and demographic variables

real-world evidence